JAK2 underexpression
|
Cutaneous Melanoma
|
JAK2 underexpression
|
Cutaneous Melanoma
|
TL-1-85 Sensitive: C3 – Early Trials
|
TL-1-85 Sensitive: C3 – Early Trials
|
JAK2 underexpression
|
Cutaneous Melanoma
|
JAK2 underexpression
|
Cutaneous Melanoma
|
QL-VIII-58 Sensitive: C3 – Early Trials
|
QL-VIII-58 Sensitive: C3 – Early Trials
|
JAK2 underexpression
|
Cutaneous Melanoma
|
JAK2 underexpression
|
Cutaneous Melanoma
|
ruxolitinib Resistant: C3 – Early Trials
|
ruxolitinib Resistant: C3 – Early Trials
|
JAK2 underexpression
|
Cutaneous Melanoma
|
JAK2 underexpression
|
Cutaneous Melanoma
|
fedratinib Resistant: C3 – Early Trials
|
fedratinib Resistant: C3 – Early Trials
|
JAK2 underexpression
|
Cutaneous Melanoma
|
JAK2 underexpression
|
Cutaneous Melanoma
|
sunitinib Resistant: C3 – Early Trials
|
sunitinib Resistant: C3 – Early Trials
|